On September 21, 2022, Lepu Medical was officially listed on the SIX Swiss Exchange. It is a critical milestone in the development of Lepu Medical and a brand new point for the company's comprehensive internationalization strategy.
The issue size was 17.68 million shares, corresponding to 88.42 million Chinese A-share shares, raising $224 million. The issue is the first GDR for a Chinese medical company on the SIX Swiss Exchange. The transaction attracted the participation of both domestic and international long-term investors. About 80% of the orders are placed by foreign investors, and the majority of those who placed orders are long-term investors, and the placement was highly concentrated in the top investors.
At the listing ceremony on September 21st, Lepu Medical was honored to have distinguished guests to celebrate this event. Mr Liu Fu Zhong, Director of the International Department of SZSE, Mr. Christian Reuss, CEO of SIX Swiss Exchange, and Joel Saurina, Counsellor of the Swiss Embassy in China all spoke highly of the efforts and contributions of Lepu Medical and congratulated this milestone event. Lepu Medical appreciates the continued support from SZSE and SIX Swiss Exchange.
Lepu Medical is dedicated to providing the full life cycle services for cardiovascular patients globally. Since its establishment in 1999 and listing on the SZSE in 2009, the company has been deeply engaged in the cardiovascular field for more than 20 years. With the production of the first domestic dual-chamber pacemaker, the first domestic coronary drug-eluting stent, the first domestic coronary bioresorbable scaffold, the first domestic coronary cutting balloon, the first biodegradable occluder and the first artificial intelligence applied to electrocardiography in the world, Lepu Medical has now grown into the leading enterprise in the cardiovascular field in China.
The GDR IPO will further help the company's international business development, and the proceeds will be used mainly for the following purposes.
(1) Establish overseas R&D center and promote the overseas clinical and registration work of innovative products. Lepu Medical will further promote the R&D of innovative products, including biodegradable occluder, TAVR, ultrasonic ablation catheter and device for renal denervation, etc. In the future, Lepu Medical will continue to promote clinical trials and registration of innovative products incardiovasular diseases outside China.
(2) Build overseas industrialization bases. Lepu Medical will further increase overseas production capacity through overseas production bases, which will help shorten the production radius, reduce production costs, provide better access to the local countries and global markets and increase the proportion of overseas sales, and further increase the company's investment in developing countries in the future.
(3) Establish global sales, after-sales network, and service system. Lepu Medical will further expand its overseas sales team and actively seek overseas partners to broaden and enhance its sales channels and service capabilities and further enhance the global awareness of Lepu Medical.
(4) Establishment of Business Development center.The BD center will support the acquisition of licenses and approvals for us and our products, and seek opportunities to co-develop products empowered by leading technologies, conduct sales and marketing activities of our products globally, and form strategic collaboration with sales, marketing and distribution partners;